These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31621991)

  • 1. BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results.
    Lalezari S; Reding MT; Pabinger I; Holme PA; Negrier C; Chalasani P; Shin HJ; Wang M; Tseneklidou-Stoeter D; Maas Enriquez M
    Haemophilia; 2019 Nov; 25(6):1011-1019. PubMed ID: 31621991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
    J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study.
    Reding MT; Pabinger I; Holme PA; Poulsen L; Negrier C; Chalasani P; Maas Enriquez M; Wang M; Meijer K; Mancuso ME; Lalezari S
    Haemophilia; 2021 May; 27(3):e347-e356. PubMed ID: 33818853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
    Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A.
    Santagostino E; Kenet G; Fischer K; Biss T; Ahuja S; Steele M
    Haemophilia; 2020 May; 26(3):e55-e65. PubMed ID: 32212300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.
    Yang R; Sun J; Zhao Y; Wang X; Wu D; Tseneklidou-Stoeter D; Wu J; Church N
    Haemophilia; 2019 May; 25(3):e153-e158. PubMed ID: 30993836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
    Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
    Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.
    Kenet G; Ljung R; Rusen L; Kerlin BA; Blanchette V; Saulytė Trakymienė S; Uscatescu V; Beckmann H; Tseneklidou-Stoeter D; Church N
    Thromb Res; 2020 May; 189():96-101. PubMed ID: 32197139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.
    Mancuso ME; Biss T; Fischer K; Maas Enriquez M; Steele M; Wang M; Tseneklidou-Stoeter D; Ahuja S; Kenet G
    Haemophilia; 2021 May; 27(3):434-444. PubMed ID: 33724632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
    Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
    Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
    Holme PA; Poulsen LH; Tueckmantel C; Maas Enriquez M; Alvarez Román MT; De Cristofaro R
    Haemophilia; 2024 Mar; 30(2):388-394. PubMed ID: 38229269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S; Maro GS; Desai V; Simpson ML
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
    Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
    Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
    Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
    Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
    Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
    Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.